Publications by authors named "Anna M van Eggermond"
Article Synopsis
- A large cohort study involving 4,919 Hodgkin lymphoma (HL) patients treated before age 51 revealed significant long-term mortality risks and treatment-related morbidity, with a notable 5.1-fold increase in deaths from non-HL causes.
- After 40 years, HL survivors had a cumulative mortality rate from non-HL causes similar to that of average 71-year-olds in the general population, indicating a major health concern for long-term survivors.
- The study highlighted that while treatments from 1989-2000 resulted in lower cardiovascular disease mortality compared to earlier periods, specific treatment approaches, like chemotherapy alone for stage I-II, showed higher HL mortality but lower overall mortality from other causes compared to radiation treatments.
Article Synopsis
- Hodgkin lymphoma survivors are at a higher risk of developing gastrointestinal (GI) cancers, and this study compares their survival rates to those of patients with first primary GI cancers.
- The analysis included 104 GI-HL patients and 1,025 GI-1 patients, matched by various factors, using Cox regression to evaluate survival outcomes while adjusting for treatment and cancer characteristics.
- Results indicate that GI-HL patients have worse overall and disease-specific survival compared to GI-1 patients, and factors like tumor stage or treatment type do not account for these survival differences.
Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We therefore examined 211 155 germline single-nucleotide polymorphisms (SNPs) for gene-radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer patients after chest RT for HL and 4671 first primary breast cancer patients.
View Article and Find Full Text PDFBackground: An increased risk of breast cancer following radiotherapy for Hodgkin lymphoma (HL) has now been robustly established. In order to estimate the dose-response relationship more accurately, and to aid clinical decision making, a retrospective estimation of the radiation dose delivered to the site of the subsequent breast cancer is required.
Methods: For 174 Dutch and 170 UK female patients with breast cancer following HL treatment, the 3-dimensional position of the breast cancer in the affected breast was determined and transferred onto a CT-based anthropomorphic phantom.
Background: Young women treated with chest radiation therapy (RT) for Hodgkin lymphoma (HL) experience a strongly increased risk of breast cancer (BC). It is unknown whether endogenous and exogenous gonadal hormones affect RT-associated BC risk.
Methods: We conducted a nested case-control study among female 5-year HL survivors treated before age 41.
Background: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens.
Methods: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates.
Background: Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of a second cancer remains unknown.
Methods: We enrolled 3905 persons in the Netherlands who had survived for at least 5 years after the initiation of treatment for Hodgkin's lymphoma.
We assessed risk, localization, and timing of third malignancies in Hodgkin lymphoma (HL) survivors. In a cohort of 3122 5-year HL survivors diagnosed before the age of 51 years and treated between 1965 and 1995, we examined whether risk factors for second and third malignancies differ and whether the occurrence of a second malignancy affects the risk of subsequent malignancies, using recurrent event analyses. After a median follow-up of 22.
View Article and Find Full Text PDFBackground: There are no published data on health preparation and travel-related morbidity in patients with inflammatory bowel disease (IBD).
Methods: A retrospective web-based questionnaire study on past travel experiences with more detailed questions concerning the most recent journey. Participants were recruited from the IBD outpatient clinic and via the website of the Dutch patient organization.